| Objective To investigate the expression of E-cad,p53,VEGF and its clinical meanings in bladder transitional cell carcinoma.Methods The immunohistochemistry was applied to detect the expression of E-cad,p53,VEGF in 62 cases of bladder transitional cell carcinoma and in 12 cases of normal control.Results Abnormal expression of E-cad,p53,VEGF were 53.2%, 58.1%, 64.5% respectively in bladder transitional cell carcinoma group. E-cad ,p53 were expressed normally and the expression of VEGF was 8.3% in the control group. There were significant differences between the two groups(P<0. 001). The abnormal expression of E-cad in bladder transitional cell carcinoma was respectively 35.3%(6/17) at Gl,48.3%(14/29) at G2 and 81.2%(13/16) at G3.The expression of p53 was respectively 35.3%(6/17) at G1, 55.2%(16/29) at G2 and 87.5%(14/16) at G3.The expression of VEGF was respectively 47.1%(8/17) at G1, 65.5%(19/29) at G2 and 81.3%(13/16) at G3.When it came to different stage, the abnormal expression of E-cad in bladder transitional cell carcinoma was respectively 33.3%(6/18) at Tis-T1 and 61.4%(27/44) at T2-T4 The expression of p53 was respectively 38.9%(7/17) at Tis-T1 and 65.9%(29/44) at T2-T4.The abnormal expression of VEGF was respectively 55.6%(10/18) at Tis-T1 and 68.2%(30/44) at T2-T4.The abnormal expression of E-cad,p53,VEGF was positively correlated with pathologic grade, stage of the carcinoma.Conclusion p53,E-cad and VEGF play an important role in the development of bladder transitional cell carcinoma. |
PDF Full Text Request